Welcome to our dedicated page for Enveric Biosciences news (Ticker: ENVB), a resource for investors and traders seeking the latest updates and insights on Enveric Biosciences stock.
Enveric Biosciences, Inc. (NASDAQ: ENVB) is a biotechnology company developing small-molecule neuroplastogenic therapeutics for psychiatric and neurological disorders. The ENVB news feed on Stock Titan aggregates company-issued press releases and other public updates so readers can follow how Enveric describes the progress of its pipeline, intellectual property estate, and capital markets activity.
Recent news from Enveric highlights several recurring themes. The company frequently reports on patent issuances and notices of allowance from the United States Patent and Trademark Office, including patents covering fused heterocyclic mescaline derivatives and N‑heterocycle substituted tryptamine derivatives within its EVM301 and EVM401 series. These announcements emphasize Enveric’s efforts to expand its portfolio of neuroplastogenic, non-hallucinogenic molecules and to strengthen composition of matter protection for potential treatments of neuropsychiatric and addiction disorders.
Another key category of ENVB news involves pipeline and preclinical development for the lead candidate EB‑003. Company updates have discussed preclinical models in post-traumatic stress disorder, dose range finding studies, chemistry and manufacturing work, and interactions with the U.S. Food and Drug Administration related to a planned Investigational New Drug submission. These items provide insight into how Enveric portrays the advancement of EB‑003 toward potential first-in-human studies.
Enveric also issues news related to financing and listing matters, such as warrant exercise inducement transactions, gross proceeds from warrant exercises, and actions taken in connection with Nasdaq listing requirements, including a reverse stock split. For investors and observers, these releases give context on how the company funds its operations and addresses exchange compliance.
By reviewing ENVB news on Stock Titan, readers can monitor Enveric’s own descriptions of its scientific progress, patent estate, financing transactions, and corporate developments over time. Investors who follow early-stage biotechnology companies may choose to consult these updates alongside the company’s SEC filings for a fuller view of the risks and plans Enveric outlines in its public communications.
Summary not available.
Summary not available.
Summary not available.
Enveric Biosciences (NASDAQ: ENVB), a biotechnology company focused on developing therapeutics for anxiety, depression, and addiction, announced participation in the Benzinga Psychedelics Capital Conference on April 13, 2023. CEO Joseph Tucker will engage in a fireside chat at 10:30 a.m. ET and a panel titled NextGen Psychedelics at 3:20 p.m. ET. The event will take place at the Fontainebleau Miami Beach.
Dr. Tucker aims to showcase Enveric's clinical development strategy, including the upcoming Phase 1 study of lead candidate EB-373 in Australia.
Enveric Biosciences (NASDAQ: ENVB) announces significant developments in their pipeline targeting mental health disorders. They've nominated EB-373 as the lead candidate for treating anxiety disorders, advancing from their EVM201 Series. A Phase 1 clinical trial is set to start in Q4 2023 in Australia, utilizing the contract research organization, Avance Clinical. Financially, the company reported a $19.3 million net loss for 2022, an improvement from the previous year's $48.8 million. The company also plans a spin-off of its cannabinoid pipeline to Akos Biosciences, Inc.. Overall, Enveric is poised for an active 2023, targeting innovations in mental health therapies.
Enveric Biosciences (NASDAQ: ENVB) announced plans to launch a first-in-human clinical trial for its lead candidate, EB-373, in Q4 2023. This proprietary psilocin prodrug targets anxiety disorders and has been designated as a New Chemical Entity by Australia’s Therapeutic Goods Administration. Enveric has partnered with Avance Clinical, an experienced contract research organization, to manage the trial, which will evaluate EB-373's safety and tolerability through a multi-cohort, dose-ascending approach. The company aims to innovate treatment options for anxiety, capitalizing on its Psybrary drug discovery platform.
Enveric Biosciences (NASDAQ: ENVB) announced groundbreaking research detailing the isolation of a novel indolethylamine N-methyltransferase from the cane toad (Rhinella marina). This discovery enables a new bioproduction platform for developing psychedelic-inspired drug candidates aimed at treating psychiatric disorders like anxiety and depression. The research was conducted by the University of Calgary and led by Dr. Peter Facchini. Enveric aims to begin human clinical trials for their lead product, EB-373, for anxiety treatment, reflecting their commitment to innovate in mental health therapeutics.
Enveric Biosciences (NASDAQ: ENVB) has appointed Kevin Coveney, CPA, as Chief Financial Officer effective March 13, 2023. With over 30 years of experience in finance and operations within the biotechnology sector, Coveney aims to lead the company's financial and capital market activities. He has a proven track record of executing growth strategies in previous roles at various biotech firms. Coveney's appointment comes at a crucial time as Enveric advances its EVM201 and EVM301 product series targeting mental health issues. As part of his induction, Coveney will receive restricted stock units convertible to 26,500 shares.
Enveric Biosciences (NASDAQ: ENVB) announced the appointment of Lynn Gallant as Vice President, Clinical Operations, effective February 22, 2023. Gallant brings over 25 years of experience in clinical operations and trial management, previously holding leadership roles at BlueRock Therapeutics and Bioverativ. She will oversee the clinical development of Enveric’s EVM201 and EVM301 product platforms. The company plans to initiate a clinical trial for its lead drug candidate, EB-373, targeting anxiety disorders. Enveric's focus is on developing novel therapeutics for mental health, leveraging its unique Psybrary™ drug discovery platform.
Enveric Biosciences (NASDAQ: ENVB), a biotechnology firm focused on developing small-molecule therapeutics for anxiety, depression, and addiction disorders, announces CEO Joseph Tucker, Ph.D., will present at the 6th Annual Growth Conference by Gravitas Securities Inc. on March 2, 2023 in Vancouver, British Columbia. Dr. Tucker's presentations include a Healthcare Panel at 1:40 p.m. PST and a Company Presentation at 2:00 p.m. PST. He will also hold one-on-one meetings with investors to discuss Enveric’s strategies, achievements, and future milestones.